#1 Clinical Trials Search in Europe

Plerixafor

This article examines the use of Plerixafor, also known as Mozobil or AMD3100, in various clinical trials focused on stem cell mobilization. Plerixafor is a drug that helps release stem cells from the bone marrow into the bloodstream, making them easier to collect for transplantation or research purposes. The trials discussed here investigate Plerixafor’s effectiveness and safety in different patient populations, including those with thalassemia, cancer, diabetes, and healthy donors.

Table of Contents

What is Plerixafor?

Plerixafor, also known by its brand names Mozobil, AMD3100, or LM-3100, is a medication used primarily to help collect stem cells from the blood for transplantation procedures[1][2]. It’s a relatively new drug that has shown promise in various medical applications, particularly in the field of hematology (the study of blood and blood-forming organs) and oncology (cancer treatment)[3].

How Plerixafor Works

Plerixafor works by blocking a specific protein called CXCR4 on the surface of stem cells. This protein normally helps keep stem cells in the bone marrow. By blocking CXCR4, Plerixafor allows stem cells to move from the bone marrow into the bloodstream, a process called mobilization[4]. This makes it easier to collect these cells for use in treatments like stem cell transplants.

In medical terms, Plerixafor is a CXCR4 antagonist. This means it prevents the CXCR4 protein from interacting with another protein called SDF-1 (Stromal Cell-Derived Factor-1), which is responsible for keeping stem cells in the bone marrow[4].

Conditions Treated with Plerixafor

Plerixafor is primarily used in the treatment of blood cancers, but research is ongoing to explore its potential in other conditions. Here are some of the main uses:

  • Multiple Myeloma: A type of blood cancer that affects plasma cells, which are a type of white blood cell[2].
  • Non-Hodgkin’s Lymphoma: A group of blood cancers that start in white blood cells called lymphocytes[5].
  • Stem Cell Mobilization: In patients who need to undergo autologous stem cell transplantation (using their own stem cells) for various conditions[1].

Ongoing research is also exploring the use of Plerixafor in other conditions, including:

  • Beta-Thalassemia: A blood disorder that reduces the production of hemoglobin[4].
  • Acute Myeloid Leukemia (AML): A type of blood and bone marrow cancer[1].
  • High-Grade Gliomas: A type of brain tumor[6].
  • Endometrial Disorders: Including conditions like Asherman’s syndrome, atrophic endometrium, and recurrent implantation failure[3].

How Plerixafor is Administered

Plerixafor is typically given as a subcutaneous injection, which means it’s injected just under the skin[2][4]. The dosage is usually based on the patient’s weight. In most cases, it’s given once daily for up to 4 days before the stem cell collection procedure.

Often, Plerixafor is used in combination with another drug called G-CSF (Granulocyte Colony-Stimulating Factor), which also helps to mobilize stem cells[2]. This combination can be particularly effective for patients who have difficulty mobilizing enough stem cells with G-CSF alone.

Potential Side Effects

Like all medications, Plerixafor can cause side effects. Most side effects reported are mild to moderate. Common side effects may include[7]:

  • Diarrhea
  • Nausea
  • Injection site reactions (such as redness or itching)
  • Dizziness
  • Headache
  • Fatigue

Serious side effects are rare but can include allergic reactions. It’s important to discuss all potential risks and side effects with your healthcare provider before starting treatment with Plerixafor.

Ongoing Research and Future Applications

Researchers are continually exploring new potential uses for Plerixafor. Some areas of ongoing research include:

  • Diabetes: Studies are investigating whether Plerixafor can help mobilize stem cells in diabetic patients, which could potentially help with complications of diabetes[7].
  • Brain Tumors: Research is being conducted on the use of Plerixafor in combination with other drugs for the treatment of high-grade gliomas, a type of brain tumor[6].
  • Endometrial Disorders: Plerixafor is being studied for its potential to help treat conditions affecting the lining of the uterus[3].
  • Improved Stem Cell Collection: Ongoing studies are looking at how Plerixafor can be used to improve stem cell collection in various patient populations, including those with blood disorders like beta-thalassemia[4].

These research efforts highlight the potential of Plerixafor to impact various areas of medicine beyond its current approved uses. As always, it’s important to remember that research takes time, and not all experimental treatments will prove to be effective or safe for widespread use.

Study Focus Patient Population Key Findings/Objectives
Beta-thalassemia Adults with beta-thalassemia major Evaluating safety and effectiveness of Plerixafor for stem cell mobilization
High-grade gliomas Patients with recurrent high-grade gliomas Assessing safety and efficacy of Plerixafor in combination with bevacizumab
Healthy donors Healthy volunteers Comparing immunological properties of Plerixafor-mobilized cells to G-CSF-mobilized cells
Diabetes Diabetic and non-diabetic subjects Comparing stem cell mobilization response to Plerixafor in diabetic vs non-diabetic individuals
Pediatric cancer Children with solid tumors Evaluating efficacy and safety of Plerixafor for stem cell mobilization in pediatric patients
Autologous transplantation Patients undergoing autologous stem cell transplant Testing altered timing of Plerixafor administration for convenience and efficacy
Allogeneic donors Healthy allogeneic stem cell donors Assessing Plerixafor as a salvage therapy for poor mobilizers

FAQ

  • What is Plerixafor and how does it work? Plerixafor, also known as Mozobil or AMD3100, is a drug that helps mobilize stem cells from the bone marrow into the bloodstream. It works by inhibiting the interaction between CXCR4 and SDF-1, which plays a role in keeping stem cells in the bone marrow.
  • In which conditions is Plerixafor being studied? Plerixafor is being studied in various conditions, including beta-thalassemia, high-grade gliomas, diabetes, and in healthy donors for stem cell collection. It's also being investigated in pediatric cancer patients and as a salvage therapy for poor stem cell mobilizers.
  • How is Plerixafor administered? Plerixafor is typically administered as a subcutaneous injection. The dosage and timing can vary depending on the study, but it's often given at a dose of 240 μg/kg, usually in the evening before stem cell collection (apheresis) the next day.
  • What are the potential side effects of Plerixafor? Common side effects of Plerixafor are generally mild and may include diarrhea, nausea, injection site reactions, dizziness, and headache. Serious side effects are rare but can include allergic reactions.
  • How does Plerixafor compare to other stem cell mobilization methods? Plerixafor is often studied in combination with or as an alternative to G-CSF (granulocyte colony-stimulating factor), another common mobilization agent. Some studies suggest that Plerixafor may be effective in patients who don't respond well to G-CSF alone.

Ongoing Clinical Trials on Plerixafor

  • Study of gene-modified stem cells (FT024) in children with TCIRG1-related osteopetrosis using treosulfan, thiotepa, and plerixafor for treatment

    Recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study on the Safety and Effectiveness of CTX001 for Children with Severe Sickle Cell Disease Using Exagamglogene Autotemcel, Busulfan, and Plerixafor

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy

  • Study on the Safety and Effectiveness of CTX001 for Children with Transfusion-Dependent Beta-Thalassemia Using Exagamglogene Autotemcel and a Drug Combination

    Recruiting

    3 1 1 1
    Investigated drugs:
    Germany Italy

  • Study on the Effects of Exagamglogene Autotemcel for Patients with Transfusion-Dependent Beta-Thalassemia or Severe Sickle Cell Disease

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy

  • Study on the Use of OTL-103 Gene Therapy and Drug Combination for Patients with Wiskott-Aldrich Syndrome

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • A Study of Gene Therapy Using Modified Stem Cells for Patients with Transfusion-Dependent Beta-Thalassemia Who Need Regular Blood Transfusions

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Effectiveness and Safety of Exa-cel for Adolescents and Adults with Severe Sickle Cell Disease

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy

  • Study on Gene Therapy with Autologous Stem Cells and Drug Combination for Children with Mucopolysaccharidosis Type I Hurler Variant

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study on Gene Therapy for Pyruvate Kinase Deficiency Using Autologous CD34+ Cells in Adults and Children

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of Exagamglogene Autotemcel (CTX001) for Treatment of Severe Sickle Cell Disease Using Modified Stem Cells

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Italy

Glossary

  • Plerixafor: A drug used to mobilize hematopoietic stem cells from the bone marrow into the bloodstream, also known as Mozobil or AMD3100.
  • Stem cell mobilization: The process of moving stem cells from the bone marrow into the bloodstream, making them easier to collect for transplantation or research.
  • CD34+ cells: A type of cell that includes hematopoietic stem cells, which can develop into various types of blood cells.
  • Apheresis: A medical procedure where blood is taken from a person and separated into its components, with some components being retained and the rest returned to the body.
  • G-CSF: Granulocyte colony-stimulating factor, a protein that stimulates the bone marrow to produce granulocytes and stem cells.
  • Hematopoietic stem cells: Immature cells that can develop into all types of blood cells, including white blood cells, red blood cells, and platelets.
  • Autologous transplantation: A procedure where a person receives their own stem cells, which were previously collected and stored.
  • Allogeneic transplantation: A procedure where a person receives stem cells from a donor, rather than their own cells.
  • Beta-thalassemia: A blood disorder that reduces the production of hemoglobin, the iron-containing protein in red blood cells that carries oxygen to cells throughout the body.
  • Glioma: A type of tumor that occurs in the brain and spinal cord.

References

  1. https://clinicaltrials.gov/study/NCT01141543
  2. https://clinicaltrials.gov/study/NCT01146834
  3. https://clinicaltrials.gov/study/NCT05343572
  4. https://clinicaltrials.gov/study/NCT01206075
  5. https://clinicaltrials.gov/study/NCT00075335
  6. https://clinicaltrials.gov/study/NCT01339039
  7. https://clinicaltrials.gov/study/NCT02056210